Aceragen, Inc.
DelistedCIK 861838fmd_0WSENQNDN3WJMPZKB63D3KRB9WManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Mar 31, 2023, 53 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 16 | 1 | 1 | 1 | – | 0 | 5 |
| Net interest income | – | (0) | (0) | – | – | – | – | – | – | – |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Research and development | 10 | 27 | 34 | 40 | 51 | 42 | 35 | 25 | 16 | 12 |
| Total operating expenses | 18 | 39 | 49 | 55 | 67 | 62 | 48 | 37 | 28 | 33 |
| Operating income | (18) | (39) | (49) | (39) | (66) | (61) | (46) | (37) | (28) | (28) |
| Interest expense | – | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Income before taxes | – | – | – | – | – | – | – | – | 98 | (30) |
| Income tax expense | – | – | – | – | – | – | – | – | 6 | (6) |
| Net income from continuing operations | – | – | – | – | – | – | – | – | 98 | (23) |
| Net income | (18) | (39) | (49) | (38) | (66) | (60) | (57) | (113) | 98 | (23) |
| Net income to common shareholders | (21) | (39) | (49) | (38) | (66) | (60) | (85) | (113) | 97 | (23) |